ArticlePloS one2015
Hepatoma-derived growth factor-related protein-3 is a novel angiogenic factor.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.International ophthalmology · 2025Review
- Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy.International journal of molecular sciences · 2024Article
- Impact of keratocyte differentiation on corneal opacity resolution and visual function recovery in male rats.Nature communications · 2024Article
- HDGFRP3 interaction with 53BP1 promotes DNA double-strand break repair.Nucleic acids research · 2023Article
- Systems biology of angiogenesis signaling: Computational models and omics.WIREs mechanisms of disease · 2022Review
- A secretory form of Parkin-independent mitophagy contributes to the repertoire of extracellular vesicles released into the tumour interstitial fluid in vivo.Journal of extracellular vesicles · 2022Article
- Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.The FEBS journal · 2022Article
- Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Motoneuron expression profiling identifies an association between an axonal splice variant of HDGF-related protein 3 and peripheral myelination.The Journal of biological chemistry · 2020Article
- Comparative Ligandomic Analysis of Human Lung Epithelial Cells Exposed to PMBiomedical and environmental sciences : BES · 2020Article
- ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS.International journal of molecular sciences · 2020Article
- Function-first ligandomics for ocular vascular research and drug target discovery.Experimental eye research · 2019Article
- Secretogranin III as a novel target for the therapy of choroidal neovascularization.Experimental eye research · 2019Article
- Ligandomics: a paradigm shift in biological drug discovery.Drug discovery today · 2018Review
- Secretogranin III: a diabetic retinopathy-selective angiogenic factor.Cellular and molecular life sciences : CMLS · 2018Review
- Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway.Biochemical and biophysical research communications · 2018Article
- Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.Angiogenesis · 2017Article
- Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.The Journal of experimental medicine · 2017Article
- The regulatory role of hepatoma-derived growth factor as an angiogenic factor in the eye.Molecular vision · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Hepatoma-derived growth factor-related protein-3 (Hdgfrp3 or HRP-3) was recently reported as a neurotrophic factor and is upregulated in hepatocellular carcinoma to promote cancer cell survival. Here we identified HRP-3 as a new endothelial ligand and characterized its in vitro and in vivo functional roles and molecular signaling. We combined open reading frame phage display with multi-round in vivo binding selection to enrich retinal endothelial ligands, which were systematically identified by next generation DNA sequencing. One of the identified endothelial ligands was HRP-3. HRP-3 expression in the retina and brain was characterized by Western blot and immunohistochemistry. Cell proliferation assay showed that HRP-3 stimulated the growth of human umbilical vein endothelial cells (HUVECs). HRP-3 induced tube formation of HUVECs in culture. Wound healing assay indicated that HRP-3 promoted endothelial cell migration. HRP-3 was further confirmed for its in vitro angiogenic activity by spheroid sprouting assay. HRP-3 extrinsically activated the extracellular-signal-regulated kinase ½ (ERK1/2) pathway in endothelial cells. The angiogenic activity of HRP-3 was independently verified by mouse cornea pocket assay. Furthermore, in vivo Matrigel plug assay corroborated HRP-3 activity to promote new blood vessel formation. These results demonstrated that HRP-3 is a novel angiogenic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.